| Literature DB >> 29255220 |
Ambra Bisio1, Ludovico Pedullà1, Laura Bonzano2, Andrea Tacchino3, Giampaolo Brichetto3,4, Marco Bove5.
Abstract
Handwriting is an important activity of daily living, which requires sensorimotor and cognitive skills that could deteriorate in presence of neurological diseases. Handwriting impairments are common in people with multiple sclerosis (PwMS). Aims of the present study were to characterize handwriting movement features of PwMS in comparison with those of healthy adults, and to evaluate the relationship between kinematic parameters of handwriting movements and the results of the assessment of cognitive and motor domains. A new handwriting evaluation methodology was applied to quantify handwriting features of 19 PwMS and 22 age-matched healthy controls who were required to write a sentence on a digitizing tablet. Kinematic parameters of the sentence and of the strokes were used to evaluate handwriting performance. PwMS showed an altered handwriting kinematics with respect to healthy controls: higher movement duration, fragmented velocity profile and higher jerk. Furthermore, motor abilities and cognitive status of PwMS were related to handwriting parameters in accordance with the evidence that MS is a multifactorial disease affecting different domains. These results suggested that the proposed methodology might be a valuable tool to quantitatively assess handwriting impairments and the efficacy of handwriting treatments in PwMS.Entities:
Mesh:
Year: 2017 PMID: 29255220 PMCID: PMC5735165 DOI: 10.1038/s41598-017-18066-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Kinematic measurements of the sentence and of the strokes.
|
|
|
| |
|---|---|---|---|
|
| |||
| Sentence duration (s) | 5.61 ± 0.34 | 7.98 ± 0.58 |
|
| Sentence length (mm) | 89.16 ± 4.99 | 92.77 ± 5.60 |
|
| Sentence height (mm) | 11.14 ± 0.78 | 12.68 ± 1.23 |
|
| Words duration (s) | 4.08 ± 0.27 | 5.59 ± 0.44 |
|
| Words length (mm) | 66.31 ± 4.04 | 70.56 ± 4.18 |
|
| Spacing between words duration (s) | 1.53 ± 0.11 | 2.38 ± 0.29 |
|
| Spacing between words length (mm) | 22.86 ± 1.36 | 22.34 ± 2.08 |
|
| CV of the sentence duration | 0.11 ± 0.05 | 0.19 ± 0.05 |
|
| CV of the sentence length | 0.04 ± 0.006 | 0.07 ± 0.01 |
|
| CV of the sentence height | 0.11 ± 0.01 | 0.14 ± 0.02 |
|
| CV of the words duration | 0.12 ± 0.02 | 0.15 ± 0.02 |
|
| CV of the words length | 0.06 ± 0.01 | 0.09 ± 0.01 |
|
| CV of spacing between words duration | 0.18 ± 0.05 | 0.28 ± 0.08 |
|
| CV of the spacing between words length | 0.09 ± 0.01 | 0.15 ± 0.02 |
|
|
| |||
| Number of strokes - NoS | 29.63 ± 1.51 | 34.40 ± 1.11 |
|
| Stroke duration (s) | 0.12 ± 0.003 | 0.14 ± 0.004 |
|
| Stroke size (mm) | 6.88 ± 0.28 | 8.37 ± 0.49 |
|
| Normalized jerk | 42.36 ± 2.23 | 64.18 ± 4.95 |
|
| Number of inversions in velocity - NIV | 1.99 ± 0.08 | 2.46 ± 0.11 |
|
| CV of NoS | 0.7 ± 0.01 | 0.7 ± 0.01 |
|
| CV of the stroke duration | 0.39 ± 0.01 | 0.40 ± 0.02 |
|
| CV of the stroke size | 0.68 ± 0.02 | 0.67 ± 0.02 |
|
| CV of the normalized jerk | 0.11 ± 0.01 | 0.12 ± 0.02 |
|
| CV of NIV | 0.06 ± 0.01 | 0.07 ± 0.01 |
|
Data are reported as mean ± standard error. No significant differences between healthy controls (HC) and people with multiple sclerosis (PwMS) are marked as “n.s.”.
Figure 1Handwriting kinematic parameters of healthy controls (HC – grey circles) and people with multiple sclerosis (PwMS, red circles). The first line shows the sentence parameters: duration of the sentence (A), words (B), and spacing between words (C). The second and third lines show stroke parameters: number of strokes (NoS - D), stroke duration (E) and length (F), number of inversion in the velocity profile (NIV - G), normalized jerk (H). Each circle represents the average value for a single subject. The horizontal line indicates the group average, and the error bars show the standard error value. * and **indicate p < 0.05 and p < 0.01, respectively.
Results from the correlation analysis between kinematic parameters and clinical scales evaluations (only significant correlations are reported).
|
|
|
|
| |
|---|---|---|---|---|
|
| ||||
| Sentence duration vs. | MLR model: R = 0.85; R2 adjusted = 0.62; p = 0.003 | |||
| NHPT |
|
|
| |
| Grip strength | − |
|
| |
| Pinch tri-pod strength |
|
|
| |
| MFIS tot | − |
|
| |
| Non-parametric (Spearman’s) correlation | ||||
| VAS for weakness |
|
| ||
| Words duration vs. | MLR model: R = 0.84; R2 adjusted = 0.58; p = 0.004 | |||
| NHPT |
|
|
| |
| SDMT | − |
|
| |
| Grip strength | − |
|
| |
| Pinch tri-pod strength |
|
|
| |
| MFIS tot | − |
|
| |
| Spacing between words duration vs. | MLR model: R = 0.72; R2 adjusted = 0.34; p = 0.04 | |||
| NHPT |
|
|
| |
| Non-parametric (Spearman) correlation | ||||
| VAS for weakness |
|
| ||
|
| ||||
| Stroke durations vs. | MLR model: R = 0.81; R2 adjusted = 0.53; p = 0.008 | |||
| NHPT |
|
|
| |
| Pinch tri-pod strength |
|
|
| |
| MFIS tot | − |
|
| |
| NIV vs. | MLR model: R = 0.85; R2 adjusted = 0.72; p = 0.003 | |||
| NHPT |
|
|
| |
| Grip strength | − |
|
| |
| Pinch tri-pod strength |
|
|
| |
| MFIS tot | − |
|
| |
| Normalized jerk vs. | MLR model: R = 0.86; R2 adjusted = 0.74; p = 0.002 | |||
| NHPT |
|
| < | |
| Grip strength | − |
|
| |
| Pinch tri-pod strength |
|
|
| |
| MFIS tot | − |
|
| |
Demographic and clinical characteristics of the patients included in the study.
| ID | Age (years) | Gender | Occupationa | MS phenotype | EDSS | Disease duration (years)b | Disease-modifying drug | Affected upper limb |
|---|---|---|---|---|---|---|---|---|
| 1 | 53 | F | Domestic worker | RR | 1.5 | 5 | — | Left |
| 2 | 32 | F | Salesgirl | RR | 4 | 8 | Fingolimod | Left |
| 3 | 61 | M | Pensioner | SP | 6 | 8 | Azatioprina | Left |
| 4 | 62 | M | Pensioner | SP | 6 | 41 | Methotrexate | Bilateral |
| 5 | 44 | F | Physical therapist | RR | 2 | 19 | Fingolimod | Right |
| 6 | 43 | F | Unemployed | RR | 6 | 23 | Interferon | Right |
| 7 | 57 | M | Pensioner | SP | 6 | 19 | Interferon | Right |
| 8 | 53 | M | Gardner | RR | 5 | 13 | — | Right |
| 9 | 31 | F | Employee | RR | 5 | 8 | Natalizumab | Bilateral |
| 10 | 47 | F | Storekeeper | RR | 2 | 10 | Interferon | Bilateral |
| 11 | 62 | M | Pensioner | RR | 5 | 6 | Fingolimod | Left |
| 12 | 55 | F | Secretary | RR | 4 | 18 | Interferon | Bilateral |
| 13 | 36 | F | Employee | RR | 2 | 9 | — | Left |
| 14 | 43 | F | Barmaid | SP | 2 | 25 | Fingolimod | Bilateral |
| 15 | 40 | F | Employee | RR | 2 | 10 | Fingolimod | Right |
| 16 | 52 | M | Pensioner | SP | 6 | 32 | — | Left |
| 17 | 27 | M | Bricklayer | RR | 2 | 5 | — | Bilateral |
| 18 | 46 | F | Housewife | RR | 4 | 22 | Fingolimod | Bilateral |
| 19 | 29 | F | Employee | RR | 1 | 8 | Fingolimod | Bilateral |
RR = relapsing–remitting; SP = secondary progressive; ain the last 10 years; bfrom diagnose.